These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36988483)

  • 1. Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial.
    Nasib LG; Winter-van Rossum I; Zuithoff NPA; Boudewijns ZSRM; Leucht S; Kahn RS
    J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36988483
    [No Abstract]   [Full Text] [Related]  

  • 2. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.
    Kahn RS; Winter van Rossum I; Leucht S; McGuire P; Lewis SW; Leboyer M; Arango C; Dazzan P; Drake R; Heres S; Díaz-Caneja CM; Rujescu D; Weiser M; Galderisi S; Glenthøj B; Eijkemans MJC; Fleischhacker WW; Kapur S; Sommer IE;
    Lancet Psychiatry; 2018 Oct; 5(10):797-807. PubMed ID: 30115598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
    Green AI; Tohen MF; Hamer RM; Strakowski SM; Lieberman JA; Glick I; Clark WS;
    Schizophr Res; 2004 Feb; 66(2-3):125-35. PubMed ID: 15061244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.
    Leucht S; Winter-van Rossum I; Heres S; Arango C; Fleischhacker WW; Glenthøj B; Leboyer M; Leweke FM; Lewis S; McGuire P; Meyer-Lindenberg A; Rujescu D; Kapur S; Kahn RS; Sommer IE
    Schizophr Bull; 2015 May; 41(3):549-58. PubMed ID: 25786408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort).
    Pandit R; Cianci D; Ter Hark SE; Winter-van Rossum I; Ebdrup BH; Broberg BV; Garcia-Portilla MP; Bobes J; Vinkers CH; Kahn RS; Guloksuz S; Huitema ADR; Luykx JJ
    Acta Psychiatr Scand; 2019 Sep; 140(3):283-290. PubMed ID: 31323113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
    Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
    J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
    Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
    J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.
    Wobrock T; Falkai P; Schneider-Axmann T; Hasan A; Galderisi S; Davidson M; Kahn RS; Derks EM; Boter H; Rybakowski JK; Libiger J; Dollfus S; López-Ibor JJ; Peuskens J; Hranov LG; Gaebel W; Fleischhacker WW;
    Schizophr Res; 2013 Jun; 147(1):132-139. PubMed ID: 23537477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
    Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu A; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Romeo R; Gray R
    Health Technol Assess; 2018 Nov; 22(67):1-62. PubMed ID: 30507375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder.
    Abdel-Baki A; Thibault D; Medrano S; Stip E; Ladouceur M; Tahir R; Potvin S
    Early Interv Psychiatry; 2020 Feb; 14(1):69-79. PubMed ID: 31125513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.
    Nasib LG; Sommer IE; Winter-van Rossum I; de Vries J; Gangadin SS; Oomen PP; Judge G; Blom RE; Luykx JJ; van Beveren NJM; Veen ND; Kroken RA; Johnsen EL
    Trials; 2020 Jun; 21(1):492. PubMed ID: 32513294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study.
    Fraguas D; Díaz-Caneja CM; Pina-Camacho L; Winter van Rossum I; Baandrup L; Sommer IE; Glenthøj B; Kahn RS; Leucht S; Arango C
    Schizophr Res; 2021 May; 231():100-107. PubMed ID: 33838518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study.
    Levi L; Bar-Haim M; Winter-van Rossum I; Davidson M; Leucht S; Fleischhacker WW; Park J; Davis JM; Kahn RS; Weiser M
    Schizophr Bull; 2023 Jul; 49(4):903-913. PubMed ID: 36999551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of depression in first episode of schizophrenia: results from EUFEST.
    Rybakowski JK; Vansteelandt K; Szafranski T; Thys E; Jarema M; Wolfgang Fleischhacker W; Kahn RS; Peuskens J;
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):875-82. PubMed ID: 22627166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.
    Slot MIE; van Hell HH; Rossum IW; Dazzan P; Maat A; de Haan L; Crespo-Facorro B; Glenthøj B; Lawrie SM; McDonald C; Gruber O; van Amelsvoort T; Arango C; Kircher T; Nelson B; Galderisi S; Weiser M; Sachs G; Maatz A; Bressan RA; Kwon JS; Mizrahi R; ; McGuire P; Kahn RS
    Schizophr Res; 2024 Apr; 266():237-248. PubMed ID: 38431986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.